Grundium oy announces the appointment of head of the U.S business and two independent board members

Tampere, Finland — Grundium Oy announced today the appointments of Joshua Griffith as head of the US operations and Andy Thomson and Chris Linthwaite as independent non-executive members of its Board of Directors, effective June, 2023.

Josh Griffith joins Grundium, bringing 18+ years of sales and marketing experience in the global diagnostics industry, driving capital equipment, consumables, and royalty revenues. Prior to joining Grundium, Josh served as Vice President of Global Marketing at Luminex – A DiaSorin Company.

Andy Thomson brings more than three decades of commercial and leadership experience to the board of Grundium. As a seasoned executive, Andy has spent significant time across the diagnostics and life sciences space through a career at three large companies. He has served as SVP EMEA and SVP and Group President of specialty Diagnostics at Thermo Fisher. Prior to joining Thermo, he was SVP and General Manager of the Centralised Diagnostics division at Roche. Before joining Roche, Andy was VP of Marketing at Dade Behring. In addition to the board of Grundium, Andy currently serves on the Boards of TubeWriter, ClearStart Inc., and Spectrum Solutions.

Chris Linthwaite is a life sciences veteran who brings experience across tools, diagnostics, and genomics. He is currently the Chief Executive Officer at Scram Systems. Prior to joining Scram, Chris served as CEO of Fluidigm since 2016. Prior to joining Fluidigm in 2016, Chris served as President of the Genetic Sciences platform at Life Technologies, managing four technology platforms across the Genetic, Medical and Applied Sciences Division.

“We are excited to welcome Josh to the Grundium team and Andy and Chris to our board of directors. Josh’s high energy and in-depth knowledge of the IVD and research market will be fundamental in leading our sales and marketing operations in the US to leverage the potential of our unique product and technology portfolio. We have wanted to establish a footprint in the US since we founded Grundium and I’m happy to establish our US operations with Josh at the helm,” said Mika Kuisma, Grundium CEO.

“We are thrilled to welcome Josh to the team and are excited to be able to work with Andy and Chris as we aggressively expand the business in the US and in the human digital pathology space. Andy and Chris’ deep expertise in life sciences tools global businesses will be invaluable to our board as we grow the business and expand the operations in particular in the US,” said Evis Hursever, Managing Director at EW Healthcare Partners and Chair of the Board of Directors.


A leader in advanced imaging technology, Grundium makes digital pathology and the best professional diagnosis available for all life – whether human, animal, plant, or other. This is achieved by applying state-of-the-art mobile technology in digital pathology. Established in 2015 by ex-Nokia engineers, the Tampere-based company is democratizing digital pathology with the Ocus® microscope scanners. The cutting-edge imaging solutions are based on over 20 years of experience in optics, sensors, and beautiful high-precision devices.


With over $4 billion raised since inception, EW Healthcare Partners makes growth equity investments in fast-growing commercial-stage healthcare companies in the pharmaceutical, medical device, diagnostics, and technology-enabled services sectors in the United States and Europe. Since its founding in 1985, EW Healthcare Partners has maintained its singular commitment to the healthcare industry and has been a long-term investor in over 150 healthcare companies ranging across sectors, stages, and geographies. The team is comprised of senior investment professionals located in their offices in New York, London, and Houston.